glp 1 chest pain Potential Use of GLP-1 and GIP/GLP-1 Receptor Agonists for Respiratory Disorders: Where Are We at? The GLP-1 Agonists and Obesity:

81,107,109 Tanzeum was discontinued by GlaxoSmithKline (GSK) in 2017, primarily due to economic factors

Abstract Glucagon-like peptide (GLP)-1 receptor agonists are the cornerstone in the treatment of hyperglycemia in many people suffering from type 2 diabetes (T2D)

For context, in one study of 175 people with overweight or obesity, participants taking semaglutide: Lost an average of 15 pounds (about 6% of their body weight) within three months Lost an average of 27 pounds (about 11% of their body weight) after six months Recommended lifestyle changes during GLP-1 therapy GLP-1 medications can boost weight loss by increasing satiety and reducing food cravings

A key consideration is that weight regain is common once someone stops a GLP-1

doi: 10.1056/NEJMcibr2409089

J Alzheimers Dis (2015) 46(4):87788